Abstract
High quality sleep is important for individuals with type 1 diabetes (T1D). Alarms associated with using diabetes technology may cause sleep disturbance. The objective of this study was to describe nighttime alarm frequency in a sample of youth using Hybrid Closed-Loop (HCL) technology and to compare alarm frequency between baseline Sensor Augmented Pump (SAP) and HCL. Youth starting the 670G participated in an observational study. Data on sensor wear, HCL use, and frequency of nighttime alarms (10pm-6am) were collected while using 670G in SAP (before starting HCL), 2 weeks after starting HCL, and during clinic visits 3, 6, 9 and 12 months after starting HCL. Forty-one youth (age 15 [12, 17] yrs, T1D duration 7.2 [4.6, 10.2] yrs, HbA1c 8.8±1.5%) were included. The median number of alarms per night with HCL use ranged from 1.4 to 2.0 across the study compared to a median of 2.1 alarms per night with baseline SAP use. There was no difference in alarm frequency with HCL use compared to SAP use (p=0.40, adjusted for percent HCL use). Experiencing two device alarms per night is likely to cause significant sleep disruption for youth and their parents, suggesting device alarms may reduce quality of life and be a barrier to diabetes technology use. Further research is needed to assess the impact of device alarms on sleep disruption for youth with T1D and their parents, and to identify strategies to reduce nighttime alarm frequency for youth using diabetes technology. Disclosure E.C. Cobry: None. C. Berget: None. L.H. Messer: Consultant; Self; Capillary Biomedical, Inc., Clinical Sensors, Inc., Dexcom, Inc., Tandem Diabetes Care. R. Wadwa: Advisory Panel; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk Inc., Tandem Diabetes Care. T.B. Vigers: None. L. Pyle: None. R.H. Slover: None. K.A. Driscoll: None. G.P. Forlenza: Advisory Panel; Self; Medtronic. Consultant; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. Funding National Institutes of Health (K12DK094712); JDRF (5-ECR-2019-736-A-N)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
